Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP076
MIFTS: 56

Hyperthyroidism

Categories: Endocrine diseases, Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hyperthyroidism

About this section

MalaCards integrated aliases for Hyperthyroidism:

Name: Hyperthyroidism 12 76 37 29 55 6 43 44 15 73
Overactive Thyroid 12 63

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Endocrine diseases Neuronal diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:7998
ICD10 33 E05.9
MeSH 44 D006980
NCIt 50 C3123
SNOMED-CT 68 34486009
KEGG 37 H01645
UMLS 73 C0020550
Sources

Summaries for Hyperthyroidism

About this section
MedlinePlus : 43 Your thyroid is a butterfly-shaped gland in your neck, just above your collarbone. It is one of your endocrine glands, which make hormones. Thyroid hormones control the rate of many activities in your body. These include how fast you burn calories and how fast your heart beats. All of these activities are your body's metabolism. If your thyroid is too active, it makes more thyroid hormones than your body needs. This is called hyperthyroidism. Hyperthyroidism is more common in women, people with other thyroid problems, and those over 60 years old. Graves' disease, an autoimmune disorder, is the most common cause. Other causes include thyroid nodules, thyroiditis, consuming too much iodine, and taking too much synthetic thyroid hormone. The symptoms can vary from person to person. They may include Being nervous or irritable Mood swings Fatigue or muscle weakness Heat intolerance Trouble sleeping Hand tremors Rapid and irregular heartbeat Frequent bowel movements or diarrhea Weight loss Goiter, which is an enlarged thyroid that may cause the neck to look swollen To diagnose hyperthyroidism, your doctor will do a physical exam, look at your symptoms, and do thyroid tests. Treatment is with medicines, radioiodine therapy, or thyroid surgery. No single treatment works for everyone. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hyperthyroidism, also known as overactive thyroid, is related to graves' disease and plummer's disease. An important gene associated with Hyperthyroidism is TSHR (Thyroid Stimulating Hormone Receptor), and among its related pathways/superpathways are Peptide ligand-binding receptors and Allograft rejection. The drugs Propylthiouracil and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include thyroid, heart and bone, and related phenotypes are Decreased HPV16-GFP infection and endocrine/exocrine gland

Disease Ontology : 12 A thyroid gland disease that involves an over production of thyroid hormone.

PubMed Health : 63 About overactive thyroid: The thyroid gland is a part of the body’s endocrine (hormone) system – which is made up of the glands that help regulate many of the body’s different functions. If the thyroid gland is overactive, it produces too much of the thyroid hormone thyroxine. An overactive thyroid (medical term: hyperthyroidism) can be caused by various things. The most common cause is a condition known as Graves disease.The higher levels of thyroid hormones unnecessarily speed up a lot of functions in the body. This can lead to noticeable symptoms such as weight loss, sweating, nervousness or a rapid heartbeat. An overactive thyroid increases the risk of cardiovascular disease (problems affecting the heart and/or blood vessels).If the thyroid gland doesn’t produce enough hormones, the body’s functions slow down. This problem is known as an underactive thyroid or hypothyroidism.

Wikipedia : 76 Hyperthyroidism is the condition that occurs due to excessive production of thyroid hormone by the... more...

Sources

Related Diseases for Hyperthyroidism

About this section

Diseases in the Hyperthyroidism family:

Familial Hyperthyroidism Due to Mutations in Tsh Receptor

Diseases related to Hyperthyroidism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 436)
# Related Disease Score Top Affiliating Genes
1 graves' disease 33.0 CTLA4 GNAS LMOD1 SERPINA7 TG THRB
2 plummer's disease 32.5 SHBG TG THRB TPO
3 thyroid crisis 32.4 SERPINA7 TG THRB
4 graves disease 1 32.4 SERPINA7 TG THRB TPO TRH TSHR
5 struma ovarii 32.4 TG TSHR
6 myxedema 32.2 CTLA4 TG TPO TSHR
7 mccune-albright syndrome 31.8 BGLAP GH1 GNAS PRL SST
8 pituitary tumors 31.7 GH1 GNAS PRL SST
9 hypothyroidism 31.0 CTLA4 GH1 GNAS LEP PRL SERPINA7
10 nodular goiter 30.7 TG TPO TSHR
11 exophthalmos 30.5 PRL TG TSHR
12 multinodular goiter 30.4 GNAS TG TPO TSHR
13 goiter 30.4 BGLAP GNAS SERPINA7 TG THRB TPO
14 neonatal hypothyroidism 30.4 TG TPO TSHR
15 thyroiditis 30.3 CTLA4 SERPINA7 TG THRB TPO TRH
16 goiter, multinodular 1, with or without sertoli-leydig cell tumors 30.2 TG TPO
17 adenoma 30.1 GH1 GNAS PRL SST TSHR
18 subacute thyroiditis 30.1 SERPINA6 SERPINA7 SHBG TG TPO TSHR
19 papillary carcinoma 30.1 TG TPO TSHR
20 thyroid cancer 30.1 BGLAP GNAS SST TG THRB TPO
21 diabetes mellitus 30.0 CTLA4 GHRL LEP SHBG SST
22 congenital hypothyroidism 30.0 GNAS SERPINA7 TG TPO TSHR
23 pernicious anemia 29.9 SST TG TPO
24 gynecomastia 29.9 CGA PRL SHBG
25 thyroid hormone resistance, generalized, autosomal dominant 29.8 SERPINA7 SHBG TG THRB TRH
26 hashimoto thyroiditis 29.8 CTLA4 TG TPO TSHR
27 hashimoto encephalopathy 29.8 TPO TSHR
28 benign struma ovarii 29.8 TG TSHR
29 chromophobe adenoma 29.7 GH1 PRL SERPINA7 TRH
30 glucose intolerance 29.7 GHRL LEP SHBG
31 thyroid cancer, nonmedullary, 2 29.6 LMOD1 SST TG THRB TPO TSHR
32 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 29.6 CTLA4 TG TPO TSHR
33 endemic goiter 29.6 SERPINA7 TG TPO TSHR
34 differentiated thyroid carcinoma 29.6 BGLAP TG TPO TSHR
35 fibrous dysplasia 29.6 BGLAP GH1 GNAS PRL SST
36 celiac disease 1 29.5 CTLA4 GHRL TG TPO
37 hypoadrenalism 29.5 GH1 SHBG TG
38 hyperthyroxinemia 29.5 SERPINA7 TPO TRH TSHR
39 prolactin producing pituitary tumor 29.4 PRL SST
40 nontoxic goiter 29.3 BGLAP SERPINA7 SHBG TG TPO TSHR
41 hyperpituitarism 29.3 GH1 PRL SST TRH
42 amenorrhea 29.3 LEP PRL SHBG TRH
43 anca-associated vasculitis 29.3 CTLA4 GHRL PRTN3
44 hyperprolactinemia 29.2 GH1 PRL SHBG SST TRH
45 diabetes mellitus, noninsulin-dependent 29.2 GH1 GHRL LEP SHBG SST
46 anorexia nervosa 29.1 GH1 GHRL LEP PRL
47 conn's syndrome 29.1 GH1 GNAS PRL SST
48 craniopharyngioma 29.1 GH1 GHRL PRL TRH
49 insulin-like growth factor i 29.1 BGLAP GH1 LEP PRL SHBG SST
50 acromegaly 29.0 GH1 GHRL GNAS PRL SST TRH

Graphical network of the top 20 diseases related to Hyperthyroidism:



Diseases related to Hyperthyroidism
Sources

Symptoms & Phenotypes for Hyperthyroidism

About this section

GenomeRNAi Phenotypes related to Hyperthyroidism according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased HPV16-GFP infection GR00350-A 8.92 GNAS SDHA SERPINA7 TRH

MGI Mouse Phenotypes related to Hyperthyroidism:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10 CGA CTLA4 GHRL GNAS LEP PRL
2 homeostasis/metabolism MP:0005376 10 CGA CTLA4 GHRL GNAS LEP PRL
3 immune system MP:0005387 9.7 CTLA4 GNAS LEP PRL PRTN3 SERPINA6
4 limbs/digits/tail MP:0005371 9.1 GNAS LEP TG THRB TPO TSHR
Sources

Drugs & Therapeutics for Hyperthyroidism

About this section

PubMedHealth treatment related to Hyperthyroidism: 63

Mild hyperthyroidism sometimes gets better on its own, without treatment. But the overproduction of thyroid hormones is usually first stopped using tablets called anti-thyroid drugs. In Graves disease, long-term treatment with this medication can make the thyroid function return to normal. If that doesn’t happen, the thyroid gland is surgically removed or treated with radioactive iodine. Known as radioiodine therapy, this involves swallowing radioactive iodine which is then absorbed by your thyroid gland, where it destroys overactive cells.If the overactive thyroid is caused by an enlarged thyroid gland with “autonomous” cells, the thyroid gland that has been “slowed down” with anti-thyroid drugs is usually surgically removed. If surgery isn’t possible or the thyroid gland isn’t greatly enlarged, radioiodine therapy tends to be more suitable.

Drugs for Hyperthyroidism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 265)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propylthiouracil Approved, Investigational Phase 4,Phase 3,Phase 2 51-52-5 657298
2
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
3
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 302-25-0
4
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Not Applicable 2921-57-5
6
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
7
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
8
Propranolol Approved, Investigational Phase 4,Phase 3,Not Applicable 525-66-6 4946
9
Methimazole Approved Phase 4,Phase 1,Phase 2,Not Applicable 60-56-0 1349907
10
Iodine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7553-56-2 807
11
Triamcinolone Approved, Vet_approved Phase 4,Not Applicable 124-94-7 31307
12
Acetylcholine Approved Phase 4,Phase 2,Phase 3 51-84-3 187
13
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1 50-02-2 5743
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 1 1177-87-3
15
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
16
Celecoxib Approved, Investigational Phase 4,Phase 2 169590-42-5 2662
17
Dinoprost Tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
18
Bimatoprost Approved, Investigational Phase 4,Phase 3,Early Phase 1 155206-00-1 5311027
19
Dinoprost Approved, Investigational Phase 4 551-11-1 5283078
20
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
21
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
22
leucovorin Approved Phase 4,Not Applicable 58-05-9 6006 143
23
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
24
Methotrexate Approved Phase 4,Not Applicable 59-05-2, 1959-05-2 126941
25
Alfacalcidol Approved, Nutraceutical Phase 4,Phase 2 41294-56-8 5282181
26
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
27
Ergocalciferol Approved, Nutraceutical Phase 4,Not Applicable 50-14-6 5280793
28
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Not Applicable 1406-16-2
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Not Applicable 59-30-3 6037
30
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Phase 3,Not Applicable 2920-86-7
31 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Antithyroid Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
35 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Not Applicable
38 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Prednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
42 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Protective Agents Phase 4,Phase 2,Phase 3,Not Applicable
44 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
45 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
46 Methylprednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
47 Ophthalmic Solutions Phase 4,Phase 2
48 Viscosupplements Phase 4,Not Applicable
49 Adjuvants, Immunologic Phase 4,Not Applicable
50 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 213)
# Name Status NCT ID Phase Drugs
1 The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy Unknown status NCT01056419 Phase 4 Propylthiouracil
2 A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy Unknown status NCT01969019 Phase 4 methylprednisolone, prednisone
3 Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Unknown status NCT01738243 Phase 4 Hyaluronic Acid Gel injection;Saline injection
4 Heart Rate Variability and Hyperthyroidism: Evaluation of the Short-term Effects of Propanolol Completed NCT03393728 Phase 4 Propanolol
5 Block-replacement Therapy During Radioiodine Therapy Completed NCT00150124 Phase 4 MTZ+LT4;Methimazole
6 Antithyroid Drugs During Radioiodine Therapy Completed NCT00150137 Phase 4 Methimazole
7 Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease Completed NCT00946296 Phase 4 Potassium Iodide
8 Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone Completed NCT00917241 Phase 4 MMI combined with IID;MMI
9 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
10 Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4 Traditional Vitamin D Therapy;Cinacalcet
11 Short-term Prednisone to Treat STA Study(SPTSS) Completed NCT01837433 Phase 4 Prednisone 1 week;Prednisone 6 weeks
12 Liver Function After Intravenous Methylprednisolone Administration Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
13 Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Completed NCT02059655 Phase 4 Bimatoprost;Eye drop solution
14 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4 Diclofenac;Methimazole;L-thyroxin;Propranolol;Metoprolol
15 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4 subconjunctival triamcinolone injection
16 Is the Routine Pressure Dressing After Thyroidectomy Necessary? Completed NCT00400465 Phase 4
17 Thermogenesis in Hyperthyroidism and Effect of Anti-Adrenergic Therapy Recruiting NCT03379181 Phase 4 Propranolol
18 Assessment of Intellectual, Psychological and Behavioural Developments Between 6 and 9 Years of the Children Born to Hyperthyroid Mothers During Their Pregnancy Recruiting NCT01779817 Phase 4
19 Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial Recruiting NCT03107078 Phase 4 Glucocorticoids
20 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
21 A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy Not yet recruiting NCT03098225 Phase 4 Methylprednisolone
22 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Not yet recruiting NCT02339142 Phase 4 intravenous corticosteroids (methylprednisolone)
23 The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Withdrawn NCT01927406 Phase 4 Prostaglandin Analog;Timolol
24 Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction Withdrawn NCT01272414 Phase 4 Botulinum Toxin Type A;Saline injection
25 Early Levothyroxine Post Radioactive Iodine Unknown status NCT01950260 Phase 2, Phase 3 Levothyroxine
26 Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy Unknown status NCT01809444 Phase 2, Phase 3 Prednisone+placebo of Doxycycline;Doxycycline+placebo of Prednisone
27 Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease Unknown status NCT00370734 Phase 2, Phase 3 Botulinum toxin A injection
28 Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism Completed NCT01039818 Phase 3
29 Early Administration of L-carnitine in Hemodialysis Patients Completed NCT00322322 Phase 3 L-Carnitine
30 Low Salt Diet in Idiopathic Hypercalciuria Completed NCT01005082 Phase 2, Phase 3
31 Percutaneous Radiofrequency Thermal Ablation in Compressive Thyroid Nodules Completed NCT01649206 Phase 3
32 Antithyroid Drug Treatment of Thyrotoxicosis in Young People Completed NCT01436994 Phase 3 carbimazole;propylthiouracil;thyroxine
33 Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues Completed NCT02155049 Phase 3 bimatoprost 0.03%
34 Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) Completed NCT01297699 Phase 3 Tocilizumab (RoActemra®);Sterile 0.9% Sodium Chloride
35 Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance Completed NCT01295333 Phase 3 the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation;The initiation of LT4 as soon as the first biological signs of hypothyroidism.
36 Trial of Rituximab for Graves' Ophthalmopathy Completed NCT00595335 Phase 2, Phase 3 Rituximab;Saline;Methylprednisolone
37 Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism Recruiting NCT03303053 Phase 3 Cholestyramine Powder 4g;Prednisolone;Standard treatment
38 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Recruiting NCT03486873 Phase 3 Standard of Care (SOC)
39 Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) Recruiting NCT03725059 Phase 3 Placebo (P);Paclitaxel (X);Doxorubicin hydrochloride (A);Epirubicin (E);Cyclophosphamide (C);Endocrine therapy
40 Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy Recruiting NCT03066076 Phase 3 Antithyroid Drug
41 Treatment of Graves´Ophthalmopathy With Diclofenac or Simvastatin (GO-DS) Recruiting NCT03131726 Phase 3 Simvastatin 40mg;Diclofenac Potassium 50 MG
42 Bupivacaine Injection of Eye Muscles to Treat Strabismus Recruiting NCT01616108 Phase 2, Phase 3 Bupivacaine
43 The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy Recruiting NCT01579539 Phase 3 Methylprednisolone;Esomeprazole
44 Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) Recruiting NCT03635567 Phase 3 Paclitaxel;Cisplatin;Carboplatin;Placebo to pembrolizumab
45 Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study Active, not recruiting NCT03298867 Phase 3
46 Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study Enrolling by invitation NCT03461211 Phase 3
47 The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease Not yet recruiting NCT02422368 Phase 2, Phase 3 Methylprednisolone + ASTED;Methylprednisolone +Placebo
48 The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) Not yet recruiting NCT02393183 Phase 2, Phase 3 ASTED
49 Role of the Microbiome in Graves' Orbitopathy Unknown status NCT02373995 Phase 1, Phase 2
50 Doxycycline Treatment in Mild Graves' Orbitopathy Unknown status NCT02203682 Phase 2 Doxycycline;placebo

Search NIH Clinical Center for Hyperthyroidism

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: hyperthyroidism

Sources

Genetic Tests for Hyperthyroidism

About this section

Genetic tests related to Hyperthyroidism:

# Genetic test Affiliating Genes
1 Hyperthyroidism 29
Sources

Anatomical Context for Hyperthyroidism

About this section

MalaCards organs/tissues related to Hyperthyroidism:

41
Thyroid, Heart, Bone, Testes, Kidney, Pituitary, Endothelial
Sources

Publications for Hyperthyroidism

About this section

Articles related to Hyperthyroidism:

(show top 50) (show all 1640)
# Title Authors Year
1
Cytomegalovirus reactivation triggers the late onset of hyperthyroidism after autologous peripheral blood transplantation. ( 30533381 )
2019
2
Rapid Remission of Graves' Hyperthyroidism Without Thionamides Under Immunosuppressive Treatment for Concomitant Autoimmune Hepatitis. ( 29336235 )
2018
3
A Case Report of Dilated Biventricular Heart Failure from Hyperthyroidism: A Rare Presentation. ( 29872591 )
2018
4
Does hyperthyroidism worsen prognosis of thyroid carcinoma? A retrospective analysis on 2820 consecutive thyroidectomies. ( 29357932 )
2018
5
Apparent Hyperthyroidism Caused by Biotin-Like Interference from IgM Anti-Streptavidin Antibodies. ( 29808739 )
2018
6
Transient Hyperthyroidism Induced by Thyroid Ultrasound. ( 29911397 )
2018
7
Does initial dosing of levothyroxine in infants with congenital hypothyroidism lead to frequent dose adjustments secondary to iatrogenic hyperthyroidism on follow-up? ( 29715192 )
2018
8
Epidemiology of childhood hyperthyroidism in France: a nationwide population-based study. ( 29846622 )
2018
9
Association of Hyperthyroidism and Thyroid Autoantibodies with Moyamoya Disease and Its Stroke Event: A Population-based Case-control Study and Meta-analysis. ( 29353860 )
2018
10
Association between Circulating Irisin Levels and Epicardial Fat in Patients with Treatment-NaA^ve Overt Hyperthyroidism. ( 29862847 )
2018
11
Differential effects of experimental hyperthyroidism on declined immunity of broiler chicken. ( 29327786 )
2018
12
A Rare Case of Thyrolipomatosis Presenting with Latent Hyperthyroidism. ( 29962723 )
2018
13
A Case of Heart Failure with Hyperthyroidism Demonstrating Discrepancy between the Clinical Course and B-type Natriuretic Peptide Levels. ( 29434126 )
2018
14
Effect of Goiter Dispersion Formula on Serum Cytokines in Hyperthyroidism Patients with Neurologic Manifestations of Graves' Disease: A Randomized Trial on 80 Cases. ( 29406821 )
2018
15
Evaluation of Serum Symmetric Dimethylarginine Concentration as a Marker for Masked Chronic Kidney Disease in Cats With Hyperthyroidism. ( 29377360 )
2018
16
Nonthionamide Drugs for the Treatment of Hyperthyroidism: From Present to Future. ( 29849619 )
2018
17
Remarkable Presentation: Anaplastic Thyroid Carcinoma Arising from Chronic Hyperthyroidism. ( 29805818 )
2018
18
High-dose biotin in infants mimics biochemical hyperthyroidism with some commercial assays. ( 29314108 )
2018
19
Energy Metabolism in the Bone is Associated with Histomorphometric Changes in Rats with Hyperthyroidism. ( 29689555 )
2018
20
Subclinical Hyperthyroidism. ( 29924956 )
2018
21
De novo SOX10 Nonsense Mutation in a Patient with Kallmann Syndrome, Deafness, Iris Hypopigmentation, and Hyperthyroidism. ( 29678855 )
2018
22
Effects of the dopamine D<sub>3</sub>receptor agonist 7-hydroxy-2-(di-N-propylamino) tetralin in hyperthyroidism-induced premature ejaculation rat model. ( 29369372 )
2018
23
A patient-specific treatment model for Graves' hyperthyroidism. ( 29310665 )
2018
24
Clinicopathological features and comorbidities of cats with mild, moderate or severe hyperthyroidism: a radioiodine referral population. ( 29432704 )
2018
25
Symptomatic hyperthyroidism in metastatic testicular mixed germ cell tumour. ( 29884717 )
2018
26
Formation of lamellar bodies in rat liver mitochondria in hyperthyroidism. ( 29721776 )
2018
27
Prevalence and risk factors for hyperthyroidism in Irish cats from the greater Dublin area. ( 29372047 )
2018
28
An update in the treatment preference for hyperthyroidism. ( 29773870 )
2018
29
Abnormal spontaneous brain activity is associated with impaired emotion and cognition in hyperthyroidism: A rs-fMRI study. ( 29885847 )
2018
30
Clinical management of childhood hyperthyroidism with and without Down syndrome: a longitudinal study at a single center. ( 29953411 )
2018
31
Cardiovascular morbidity and mortality after treatment of hyperthyroidism with either radioactive iodine or thyroidectomy. ( 29882483 )
2018
32
Narcolepsy with cataplexy and hyperthyroidism sudden appeared after H1N1 vaccination. ( 29796199 )
2018
33
Both experimental hypothyroidism and hyperthyroidism increase cardiac irisin levels in rats. ( 29405728 )
2018
34
Adult-Onset Sleepwalking Secondary to Hyperthyroidism: Polygraphic Evidence. ( 29246269 )
2018
35
Selenium in Graves Hyperthyroidism and Orbitopathy. ( 29933354 )
2018
36
The Effect of Experimental Hyperthyroidism on Characteristics of Actin-Myosin Interaction in Fast and Slow Skeletal Muscles. ( 29738686 )
2018
37
A Rare Case of Thyrotropin-Secreting Pituitary Adenoma Coexisting with Papillary Thyroid Carcinoma Presenting with Visual Disturbance without Hyperthyroidism. ( 30096503 )
2018
38
Plasma endothelin-1 levels are increased in atrial fibrillation patients with hyperthyroidism. ( 30513109 )
2018
39
A Pediatric Case of Graves' Hyperthyroidism with Associated Glucose Intolerance Detected by a Urine Glucose Screening Program at School. ( 30224619 )
2018
40
Euthyroid Graves' disease with spurious hyperthyroidism: a diagnostic challenge. ( 30204589 )
2018
41
Alternating hyperthyroidism and hypothyroidism in Graves' disease. ( 30214742 )
2018
42
Incidence of neonatal hyperthyroidism among newborns of Graves' disease patients treated with radioiodine therapy. ( 30426886 )
2018
43
RNASET2, GPR174, and PTPN22 gene polymorphisms are related to the risk of liver damage associated with the hyperthyroidism in patients with Graves' disease. ( 28568286 )
2018
44
Serum microRNA miR-206 is decreased in hyperthyroidism and mediates thyroid hormone regulation of lipid metabolism in HepG2 human hepatoblastoma cells. ( 29484422 )
2018
45
Hypothyroidism conversion to hyperthyroidism: it's never too late. ( 30083349 )
2018
46
Diagnosis and management of hyperthyroidism from prenatal life to adolescence. ( 30086864 )
2018
47
Preoperative Preparation of Hyperthyroidism for Thyroidectomy - Role of Supersaturated Iodine and Lithium Carbonate. ( 30090733 )
2018
48
Ventricular Fibrillation Induced by Coronary Vasospasm in a Patient with Early Repolarization and Hyperthyroidism. ( 30101915 )
2018
49
Hyperthyroidism with Selective Immunoglobulin A Deficiency. ( 30101931 )
2018
50
The Relation Between Epicardial Fat Tissue Thickness and TSH Receptor Antibody in Hyperthyroidism. ( 30107622 )
2018
Sources

Variations for Hyperthyroidism

About this section
Sources

Expression for Hyperthyroidism

About this section
Search GEO for disease gene expression data for Hyperthyroidism.
Sources

Pathways for Hyperthyroidism

About this section

Pathways related to Hyperthyroidism according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 66
Show member pathways
 12.92 CGA GH1 GHRL GNAS LEP PRL
2
Allograft rejection 1 37
Show member pathways
 12.63 CGA CTLA4 TG TPO TSHR
3
Aldosterone synthesis and secretion 37
Show member pathways
 12.31 CGA GNAS SERPINA7 TG TPO TSHR
4
Prolactin Signaling Pathway 1 37
Show member pathways
 12.23 CGA GH1 LEP PRL
5
Peptide hormone metabolism 66
Show member pathways
 11.93 CGA GH1 GHRL LEP
6
Glucocorticoid receptor regulatory network 1
11.52 BGLAP CGA PRL
7
Human Thyroid Stimulating Hormone (TSH) signaling pathway 1
11.41 CGA GNAS TSHR
8
Regulation of lipolysis in adipocytes 37
11.23 CGA GNAS TSHR
9
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.09 BGLAP CGA THRB
10
Hormone ligand-binding receptors 66
10.57 CGA TSHR
11
Thyroxine (Thyroid Hormone) Production 1
9.8 CGA TG TPO TRH TSHR
Sources

GO Terms for Hyperthyroidism

About this section

Cellular components related to Hyperthyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 BGLAP CGA GH1 GHRL LEP PRL
2 extracellular region GO:0005576 9.47 BGLAP CGA GH1 GHRL GNAS LEP
3 endosome lumen GO:0031904 9.16 GH1 PRL

Biological processes related to Hyperthyroidism according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.95 CGA LEP PRL PRTN3 TSHR
2 response to drug GO:0042493 9.88 BGLAP GNAS PRL SST
3 response to estradiol GO:0032355 9.75 GH1 LEP PRL
4 female pregnancy GO:0007565 9.73 GNAS LEP PRL
5 response to ethanol GO:0045471 9.71 BGLAP LEP PRL TRH
6 response to nutrient GO:0007584 9.65 LEP PRL SST
7 positive regulation of multicellular organism growth GO:0040018 9.61 GH1 GHRL TSHR
8 energy reserve metabolic process GO:0006112 9.57 GNAS LEP
9 positive regulation of cold-induced thermogenesis GO:0120162 9.56 GHRL GNAS LEP TSHR
10 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.54 GH1 PRL
11 positive regulation of JAK-STAT cascade GO:0046427 9.54 GH1 LEP PRL
12 hormone biosynthetic process GO:0042446 9.52 TG TPO
13 positive regulation of growth GO:0045927 9.51 GH1 GHRL
14 thyroid gland development GO:0030878 9.5 CGA TG THRB
15 thyroid hormone generation GO:0006590 9.49 CGA TPO
16 adult feeding behavior GO:0008343 9.46 GHRL LEP
17 hormone-mediated signaling pathway GO:0009755 9.46 GHRL THRB TRH TSHR
18 response to nutrient levels GO:0031667 9.35 BGLAP GH1 GHRL LEP PRL
19 regulation of signaling receptor activity GO:0010469 9.23 CGA GH1 GHRL LEP PRL SST

Molecular functions related to Hyperthyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.23 CGA GH1 GHRL LEP PRL SST
2 prolactin receptor binding GO:0005148 8.96 GH1 PRL
Sources

Sources for Hyperthyroidism

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....